Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 298

1.

Infantile Nephrocalcinosis Resulting From a Pathogenic CYP24A1 Mutation.

Murphy JD, Joseph M, Larsen CP.

Kidney Int Rep. 2019 Apr 29;4(6):893-897. doi: 10.1016/j.ekir.2019.04.016. eCollection 2019 Jun. No abstract available.

2.

Corticosteroids and methotrexate as adjuvants to costimulation blockade in non-human primate renal transplantation.

Anderson DJ, Lo DJ, Leopardi F, Song M, Strobert EA, Jenkins JB, Larsen CP, Kirk AD.

Clin Transplant. 2019 Apr 21:e13568. doi: 10.1111/ctr.13568. [Epub ahead of print]

PMID:
31006146
3.

Anti-LRP2 Nephropathy With Abundant IgG4-Positive Plasma Cells: A Case Report.

Dinesh KP, Raniele D, Michels K, Avasare RS, Larsen CP, Kayton R, Khalighi MA, Andeen NK.

Am J Kidney Dis. 2019 Mar 12. pii: S0272-6386(19)30085-X. doi: 10.1053/j.ajkd.2018.12.039. [Epub ahead of print]

PMID:
30876746
4.

Long-term survival of pig-to-rhesus macaque renal xenografts is dependent on CD4 T cell depletion.

Kim SC, Mathews DV, Breeden CP, Higginbotham LB, Ladowski J, Martens G, Stephenson A, Farris AB, Strobert EA, Jenkins J, Walters EM, Larsen CP, Tector M, Tector AJ, Adams AB.

Am J Transplant. 2019 Mar 1. doi: 10.1111/ajt.15329. [Epub ahead of print]

PMID:
30821922
5.

Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.

Badell IR, Karadkhele GM, Vasanth P, Farris AB 3rd, Robertson JM, Larsen CP.

Am J Transplant. 2019 Feb 15. doi: 10.1111/ajt.15319. [Epub ahead of print]

PMID:
30768841
6.

Kinetics of antibody response to influenza vaccination in renal transplant recipients.

Gangappa S, Wrammert J, Wang D, Li ZN, Liepkalns JS, Cao W, Chen J, Levine MZ, Stevens J, Sambhara S, Begley B, Mehta A, Pearson TC, Ahmed R, Larsen CP.

Transpl Immunol. 2019 Apr;53:51-60. doi: 10.1016/j.trim.2019.01.001. Epub 2019 Jan 18.

PMID:
30664927
7.

α1-Heavy Chain Deposition Disease With Negative Immunofluorescence Staining on Renal Biopsy.

Best Rocha A, Larsen CP, Delyria PA, Polavaram LS, Said SM, Shibata RS, Rech KL, Nasr SH.

Kidney Int Rep. 2018 Sep 18;4(1):178-183. doi: 10.1016/j.ekir.2018.09.007. eCollection 2019 Jan. No abstract available.

8.

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0102-7.

PMID:
30568288
9.

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Jan;15(1):45-59. doi: 10.1038/s41581-018-0077-4. Review. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121.

PMID:
30510265
10.

The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms.

Gopalsamy SN, Woodworth MH, Wang T, Carpentieri CT, Mehta N, Friedman-Moraco RJ, Mehta AK, Larsen CP, Kraft CS.

Am J Med Sci. 2018 Nov;356(5):433-440. doi: 10.1016/j.amjms.2018.08.015. Epub 2018 Aug 29.

PMID:
30384952
11.

Renal Manifestations of Inflammatory Bowel Disease.

Ambruzs JM, Larsen CP.

Rheum Dis Clin North Am. 2018 Nov;44(4):699-714. doi: 10.1016/j.rdc.2018.06.007. Epub 2018 Sep 7. Review.

12.

Tree species richness predicted using a spatial environmental model including forest area and frost frequency, eastern USA.

Kwon Y, Larsen CPS, Lee M.

PLoS One. 2018 Sep 18;13(9):e0203881. doi: 10.1371/journal.pone.0203881. eCollection 2018.

13.

CD122 signaling in CD8+ memory T cells drives costimulation-independent rejection.

Mathews DV, Dong Y, Higginbotham LB, Kim SC, Breeden CP, Stobert EA, Jenkins J, Tso JY, Larsen CP, Adams AB.

J Clin Invest. 2018 Oct 1;128(10):4557-4572. doi: 10.1172/JCI95914. Epub 2018 Sep 17.

14.

Patient Navigators in Transplantation - where do we go from here?

Patzer RE, Larsen CP.

Transplantation. 2018 Sep 11. doi: 10.1097/TP.0000000000002451. [Epub ahead of print] No abstract available.

PMID:
30211829
15.

Karyomegalic interstitial nephritis in a renal allograft.

Ravindran A, Cortese C, Larsen CP, Wadei HM, Gandhi MJ, Cosio FG, Sethi S.

Am J Transplant. 2019 Jan;19(1):285-290. doi: 10.1111/ajt.15035. Epub 2018 Aug 20.

PMID:
30040181
16.

Fluorescence in situ hybridization for the diagnosis of NPHP1 deletion-related nephronophthisis on renal biopsy.

Larsen CP, Bonsib SM, Beggs ML, Wilson JD.

Hum Pathol. 2018 Nov;81:71-77. doi: 10.1016/j.humpath.2018.06.021. Epub 2018 Jun 24.

17.

Congophilic Fibrillary Glomerulonephritis: A Case Series.

Alexander MP, Dasari S, Vrana JA, Riopel J, Valeri AM, Markowitz GS, Hever A, Bijol V, Larsen CP, Cornell LD, Fidler ME, Said SM, Sethi S, Herrera Hernandez LP, Grande JP, Erickson SB, Fervenza FC, Leung N, Kurtin PJ, Nasr SH.

Am J Kidney Dis. 2018 Sep;72(3):325-336. doi: 10.1053/j.ajkd.2018.03.017. Epub 2018 Jun 14.

PMID:
29866458
18.

Transplant Center Patient Navigator and Access to Transplantation among High-Risk Population: A Randomized, Controlled Trial.

Basu M, Petgrave-Nelson L, Smith KD, Perryman JP, Clark K, Pastan SO, Pearson TC, Larsen CP, Paul S, Patzer RE.

Clin J Am Soc Nephrol. 2018 Apr 6;13(4):620-627. doi: 10.2215/CJN.08600817. Epub 2018 Mar 26.

19.

Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.

Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP.

Am J Transplant. 2018 Jul;18(7):1774-1782. doi: 10.1111/ajt.14738. Epub 2018 Apr 17.

20.

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.

Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP.

Am J Transplant. 2018 Jul;18(7):1783-1789. doi: 10.1111/ajt.14721. Epub 2018 Apr 2.

21.

Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.

Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Garcia VD, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Yang L, Medina Pestana J, Larsen CP.

Clin Transplant. 2018 Apr;32(4):e13225. doi: 10.1111/ctr.13225. Epub 2018 Mar 14.

PMID:
29461660
22.

Effect of the iChoose Kidney decision aid in improving knowledge about treatment options among transplant candidates: A randomized controlled trial.

Patzer RE, McPherson L, Basu M, Mohan S, Wolf M, Chiles M, Russell A, Gander JC, Friedewald JJ, Ladner D, Larsen CP, Pearson T, Pastan S.

Am J Transplant. 2018 Aug;18(8):1954-1965. doi: 10.1111/ajt.14693. Epub 2018 Mar 26.

23.

Membranous Glomerulopathy With Light Chain-Restricted Deposits: A Clinicopathological Analysis of 28 Cases.

Best Rocha A, Larsen CP.

Kidney Int Rep. 2017 Jul 29;2(6):1141-1148. doi: 10.1016/j.ekir.2017.07.008. eCollection 2017 Nov.

24.

Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study.

Sharma SG, Larsen CP.

Mod Pathol. 2018 Apr;31(4):616-622. doi: 10.1038/modpathol.2017.163. Epub 2017 Dec 15.

25.

Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy.

Larsen CP, Wilson JD, Best-Rocha A, Beggs ML, Hennigar RA.

Mod Pathol. 2018 Mar;31(3):488-494. doi: 10.1038/modpathol.2017.154. Epub 2017 Nov 17.

26.

Emergency department use among kidney transplant recipients in the United States.

Lovasik BP, Zhang R, Hockenberry JM, Schrager JD, Pastan SO, Adams AB, Mohan S, Larsen CP, Patzer RE.

Am J Transplant. 2018 Apr;18(4):868-880. doi: 10.1111/ajt.14578. Epub 2017 Dec 20.

27.

LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease.

Larsen CP, Trivin-Avillach C, Coles P, Collins AB, Merchant M, Ma H, Wilkey DW, Ambruzs JM, Messias NC, Cossey LN, Rosales IA, Wooldridge T, Walker PD, Colvin RB, Klein J, Salant DJ, Beck LH Jr.

J Am Soc Nephrol. 2018 Feb;29(2):644-653. doi: 10.1681/ASN.2017060664. Epub 2017 Oct 26.

28.

Collapsing glomerulopathy: a 30-year perspective and single, large center experience.

Nicholas Cossey L, Larsen CP, Liapis H.

Clin Kidney J. 2017 Aug;10(4):443-449. doi: 10.1093/ckj/sfx029. Epub 2017 May 8.

29.

Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.

Vincenti F, Blancho G, Durrbach A, Grannas G, Grinyó J, Meier-Kriesche HU, Polinsky M, Yang L, Larsen CP.

Am J Transplant. 2017 Dec;17(12):3219-3227. doi: 10.1111/ajt.14452. Epub 2017 Sep 5.

30.

Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept.

Newell KA, Mehta AK, Larsen CP, Stock PG, Farris AB, Mehta SG, Ikle D, Armstrong B, Morrison Y, Bridges N, Robien M, Mannon RB.

Am J Transplant. 2017 Oct;17(10):2712-2719. doi: 10.1111/ajt.14377. Epub 2017 Jul 3.

31.

Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.

Adams AB, Goldstein J, Garrett C, Zhang R, Patzer RE, Newell KA, Turgeon NA, Chami AS, Guasch A, Kirk AD, Pastan SO, Pearson TC, Larsen CP.

Am J Transplant. 2017 Nov;17(11):2922-2936. doi: 10.1111/ajt.14353. Epub 2017 Jul 3.

32.

Belatacept-Resistant Rejection Is Associated With CD28+ Memory CD8 T Cells.

Mathews DV, Wakwe WC, Kim SC, Lowe MC, Breeden C, Roberts ME, Farris AB, Strobert EA, Jenkins JB, Larsen CP, Ford ML, Townsend R, Adams AB.

Am J Transplant. 2017 Sep;17(9):2285-2299. doi: 10.1111/ajt.14349. Epub 2017 Jul 11.

33.

Increased Pretransplant Frequency of CD28+ CD4+ TEM Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients.

Cortes-Cerisuelo M, Laurie SJ, Mathews DV, Winterberg PD, Larsen CP, Adams AB, Ford ML.

Am J Transplant. 2017 Sep;17(9):2350-2362. doi: 10.1111/ajt.14350. Epub 2017 Jun 30.

34.

Interruption of OX40L signaling prevents costimulation blockade-resistant allograft rejection.

Kitchens WH, Dong Y, Mathews DV, Breeden CP, Strobert E, Fuentes ME, Larsen CP, Ford ML, Adams AB.

JCI Insight. 2017 Mar 9;2(5):e90317. doi: 10.1172/jci.insight.90317.

35.

Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.

Kim SC, Wakwe W, Higginbotham LB, Mathews DV, Breeden CP, Stephenson AC, Jenkins J, Strobert E, Price K, Price L, Kuhn R, Wang H, Yamniuk A, Suchard S, Farris AB 3rd, Pearson TC, Larsen CP, Ford ML, Suri A, Nadler S, Adams AB.

Am J Transplant. 2017 May;17(5):1182-1192. doi: 10.1111/ajt.14197. Epub 2017 Feb 25.

36.

Purified Human Pancreatic Islets, CIT Culture Media with Lisofylline or Exenatide.

NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee, Ansite J, Balamurugan AN, Barbaro B, Battle J, Brandhorst D, Cano J, Chen X, Deng S, Feddersen D, Friberg A, Gilmore T, Goldstein JS, Holbrook E, Khan A, Kin T, Lei J, Linetsky E, Liu C, Luo X, McElvaney K, Min Z, Moreno J, O'Gorman D, Papas KK, Putz G, Ricordi C, Szot G, Templeton T, Wang L, Wilhelm JJ, Willits J, Wilson T, Zhang X; NIH CIT Consortium, Avila J, Begley B, Cano J, Carpentier S, Holbrook E, Hutchinson J, Larsen CP, Moreno J, Sears M, Turgeon NA, Webster D, Deng S, Lei J, Markmann JF, Bridges ND, Czarniecki CW, Goldstein JS, Putz G, Templeton T, Wilson T, Eggerman TL, Al-Saden P, Battle J, Chen X, Hecyk A, Kissler H, Luo X, Molitch M, Monson N, Stuart E, Wallia A, Wang L, Wang S, Zhang X, Bigam D, Campbell P, Dinyari P, Kin T, Kneteman N, Lyon J, Malcolm A, O'Gorman D, Onderka C, Owen R, Pawlick R, Richer B, Rosichuk S, Sarman D, Schroeder A, Senior PA, Shapiro AMJ, Toth L, Toth V, Zhai W, Johnson K, McElroy J, Posselt AM, Ramos M, Rojas T, Stock PG, Szot G, Barbaro B, Martellotto J, Oberholzer J, Qi M, Wang Y, Bayman L, Chaloner K, Clarke W, Dillon JS, Diltz C, Doelle GC, Ecklund D, Feddersen D, Foster E, Hunsicker LG, Jasperson C, Lafontant DE, McElvaney K, Neill-Hudson T, Nollen D, Qidwai J, Riss H, Schwieger T, Willits J, Yankey J, Alejandro R, Corrales AC, Faradji R, Froud T, Garcia AA, Herrada E, Ichii H, Inverardi L, Kenyon N, Khan A, Linetsky E, Montelongo J, Peixoto E, Peterson K, Ricordi C, Szust J, Wang X, Abdulla MH, Ansite J, Balamurugan AN, Bellin MD, Brandenburg M, Gilmore T, Harmon JV, Hering BJ, Kandaswamy R, Loganathan G, Mueller K, Papas KK, Pedersen J, Wilhelm JJ, Witson J, Dalton-Bakes C, Fu H, Kamoun M, Kearns J, Li Y, Liu C, Luning-Prak E, Luo Y, Markmann E, Min Z, Naji A, Palanjian M, Rickels M, Shlansky-Goldberg R, Vivek K, Ziaie AS, Fernandez L, Kaufman DB, Zitur L, Brandhorst D, Friberg A, Korsgren O.

CellR4 Repair Replace Regen Reprogram. 2017;5(3). pii: e2377. Epub 2017 May 26. No abstract available.

37.

Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant.

Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, Carvalho D, Grannas G, Muehlbacher F, O'Connell PJ, Meier-Kriesche HU, Larsen CP.

Am J Transplant. 2017 Jan;17(1):180-190. doi: 10.1111/ajt.13886. Epub 2016 Jul 12.

38.

First-Year Waitlist Hospitalization and Subsequent Waitlist and Transplant Outcome.

Lynch RJ, Zhang R, Patzer RE, Larsen CP, Adams AB.

Am J Transplant. 2017 Apr;17(4):1031-1041. doi: 10.1111/ajt.14061. Epub 2016 Oct 24.

39.

Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway.

Adams AB, Ford ML, Larsen CP.

J Immunol. 2016 Sep 15;197(6):2045-50. doi: 10.4049/jimmunol.1601135. Review.

40.

Clinicopathologic Features of Membranous-Like Glomerulopathy With Masked IgG Kappa Deposits.

Larsen CP, Boils CL, Cossey LN, Sharma SG, Walker PD.

Kidney Int Rep. 2016 Aug 24;1(4):299-305. doi: 10.1016/j.ekir.2016.08.012. eCollection 2016 Nov.

41.

The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques.

Zheng HB, Watkins B, Tkachev V, Yu S, Tran D, Furlan S, Zeleski K, Singh K, Hamby K, Hotchkiss C, Lane J, Gumber S, Adams AB, Cendales L, Kirk AD, Kaur A, Blazar BR, Larsen CP, Kean LS.

Am J Transplant. 2017 Mar;17(3):657-670. doi: 10.1111/ajt.14006. Epub 2016 Sep 19.

42.

Enhanced Requirement for TNFR2 in Graft Rejection Mediated by Low-Affinity Memory CD8+ T Cells during Heterologous Immunity.

Krummey SM, Chen CW, Guasch SA, Liu D, Wagener M, Larsen CP, Ford ML.

J Immunol. 2016 Sep 1;197(5):2009-15. doi: 10.4049/jimmunol.1502680. Epub 2016 Aug 1.

43.

The Authors Reply.

Larsen CP, Walker PD.

Kidney Int. 2016 Jul;90(1):225. doi: 10.1016/j.kint.2016.03.013. No abstract available.

PMID:
27312451
44.

Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia.

Hering BJ, Clarke WR, Bridges ND, Eggerman TL, Alejandro R, Bellin MD, Chaloner K, Czarniecki CW, Goldstein JS, Hunsicker LG, Kaufman DB, Korsgren O, Larsen CP, Luo X, Markmann JF, Naji A, Oberholzer J, Posselt AM, Rickels MR, Ricordi C, Robien MA, Senior PA, Shapiro AM, Stock PG, Turgeon NA; Clinical Islet Transplantation Consortium.

Diabetes Care. 2016 Jul;39(7):1230-40. doi: 10.2337/dc15-1988. Epub 2016 Apr 18.

45.

Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico.

Larsen CP, Beggs ML, Wilson JD, Lathrop SL.

Amyloid. 2016 Jun;23(2):119-23. doi: 10.3109/13506129.2016.1145110. Epub 2016 Feb 25.

46.

Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians.

Larsen CP, Ismail W, Kurtin PJ, Vrana JA, Dasari S, Nasr SH.

Mod Pathol. 2016 Apr;29(4):416-20. doi: 10.1038/modpathol.2016.29. Epub 2016 Feb 12.

47.

Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity.

Krummey SM, Martinez RJ, Andargachew R, Liu D, Wagener M, Kohlmeier JE, Evavold BD, Larsen CP, Ford ML.

J Immunol. 2016 Mar 15;196(6):2838-46. doi: 10.4049/jimmunol.1500639. Epub 2016 Feb 10.

48.

APOL1 Polymorphisms in a Deceased Donor and Early Presentation of Collapsing Glomerulopathy and Focal Segmental Glomerulosclerosis in Two Recipients.

Shah PB, Cooper JE, Lucia MS, Boils C, Larsen CP, Wiseman AC.

Am J Transplant. 2016 Jun;16(6):1923-1927. doi: 10.1111/ajt.13748. Epub 2016 Mar 29.

49.

THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity.

Larsen CP, Cossey LN, Beck LH.

Mod Pathol. 2016 Apr;29(4):421-6. doi: 10.1038/modpathol.2016.32. Epub 2016 Feb 5.

50.

Belatacept and Long-Term Outcomes in Kidney Transplantation.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP.

N Engl J Med. 2016 Jan 28;374(4):333-43. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med. 2016 Feb 18;374(7):698.

Supplemental Content

Loading ...
Support Center